#specialty drugs

1 story

#amneal pharmaceuticals #amrx #barclays #generic drugs #mid-cap stocks #pharmaceutical stocks #price target increase #stock upgrade #wall street analyst

Amneal jumps 6.4% on Barclays upgrade
Barclays raises its price target on the drugmaker by 25%, signaling confidence in the company's near-term prospects.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m